


**Product Name** : ZLDI-8  
**Cat. No.** : PC-35373  
**CAS No.** : 667880-38-8  
**Molecular Formula** : C<sub>24</sub>H<sub>23</sub>N<sub>3</sub>O<sub>3</sub>S  
**Molecular Weight** : 433.526  
**Target** : Matrix Metalloproteinase (MMP)  
**Solubility** : 10 mM in DMSO



### Biological Activity

ZLDI-8 (IAC-8) is a novel Notch signaling pathway inhibitor for Notch activating/cleaving enzyme **ADAM-17** (TNF $\alpha$ -converting enzyme, or TACE), significantly decreases the level of NICD and accumulation of NICD in the nucleus. ZLDI-8 (IAC-8) exhibits cytotoxic activity against MHCC97-H cells with IC<sub>50</sub> of 5.32  $\mu$ M, reduces the expression of pro-survival/anti-apoptosis regulators, Survivin and cIAP1/2, also increases the expression of epithelial marker E-Cadherin and reduces mesenchymal markers N-Cadherin and Vimentin in HCC cells.

ZLDI-8 (IAC-8) significantly disrupted the activity of Notch pathway in HCC cells and inhibits the epithelial-mesenchymal transition (EMT) process of HCC cells.

ZLDI-8 (IAC-8) treatment enhances the susceptibility of HCC cells to Sorafenib, Etoposide, and Paclitaxel both in vitro and in vivo.

### References

Zhang Y, et al. *Cell Death Dis.* 2018 Jul 3;9(7):743.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com